Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

Blood (2023) 142 (Supplement 1): 323.

https://doi.org/10.1182/blood-2023-184703

Published: 2023

Journal Articles

The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1572.

https://doi.org/10.1182/blood-2023-181709

Published: 2023

Journal Articles

Impact of Hemodilution on Measurable Residual Disease Measured Via Flow-Cytometry in Acute Myeloid Leukemia Analyzed Using Subsequent Pulls

Jesse M. Tettero, Maaike Heidinga, Tim R. Mocking, Glenn Fransen, Ezra S Beerman, Angèle Kelder, Willemijn Scholten, Alexander N. Snel, Lok Lam Ngai, Costa Bachas, Arjan A. Van de Loosdrecht, Gert Ossenkoppele, David C. de Leeuw, Jeroen J.W.M. Janssen, Jacqueline Cloos

Blood (2023) 142 (Supplement 1): 1559.

https://doi.org/10.1182/blood-2023-179242

Published: 2023

Journal Articles

Prospective validation of the prognostic relevance of CD34 + CD38 – AML stem cell frequency in the HOVON-SAKK132 trial

Blood (2023) 141 (21): 2657–2661.

https://doi.org/10.1182/blood.2022019160

Published: 2023

Includes: Supplemental data

Journal Articles

Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Blood (2022) 140 (Supplement 1): 9125–9127.

https://doi.org/10.1182/blood-2022-157753

Published: 2022

Journal Articles

Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching

Jesse M. Tettero, Lok Lam Ngai, Costa Bachas, Dimitri A. Breems, Thomas Fischer, Bjørn Tore Gjertsen, Patrycja Gradowska, Laimonas Griskevicius, Jeroen J.W.M. Janssen, Gunnar Juliusson, Johan A. Maertens, Markus G Manz, Thomas Pabst, Jakob Passweg, Kimmo Porkka, Peter JM Valk, Bob Lowenberg, Gert J. Ossenkoppele, Jacqueline Cloos

Blood (2022) 140 (Supplement 1): 2027–2029.

https://doi.org/10.1182/blood-2022-157009

Published: 2022

Journal Articles

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Blood (2021) 138 (26): 2753–2767.

https://doi.org/10.1182/blood.2021013626

Published: 2021

Includes: Supplemental data

Journal Articles

Machine Learning-Based Flow Cytometry Diagnostics in Myelodysplastic Syndromes: Validation in the HOVON89 Clinical Trial (EudraCT 2008-002195-10)

Carolien Duetz, MD, Sofie Van Gassen, PhD, Theresia M. Westers, PhD, Florentien in t Hout, MDPhD, Eline Cremers, MDPhD, Canan Alhan, MD PhD, Costa Bachas, PhD, Margot F. Van Spronsen, MD, Heleen Visser-Wisselaar, Dana Chitu, Aniek O. De Graaf, PhD, Joop Jansen, PhD, Yvan Saeys, PhD, Arjan van de Loosdrecht, MD PhD

Blood (2020) 136 (Supplement 1): 10–12.

https://doi.org/10.1182/blood-2020-136719

Published: 2020

Journal Articles

Frequency and Prognostic Relevance of Gene Mutations in Pediatric AML Patients At First Relapse.

Costa Bachas, MSc, Gerrit Jan Schuurhuis, PhD, Dirk Reinhardt, MD, Ursula Creutzig, MD, PhD, Zinia J. Kwidama, BSc, C. Michel Zwaan, MD, PhD, Marry M. van den Heuvel-Eibrink, Evelina S De Bont, MD, PhD, Sara Elitzur, MD, Carmelo Rizzari, MD, PhD, Valérie de Haas, MD, PhD, Martin Zimmermann, Jacqueline Cloos, PhD, Gertjan J.L. Kaspers, MD, PhD

Blood (2012) 120 (21): 2480.

https://doi.org/10.1182/blood.V120.21.2480.2480

Published: 2012

Journal Articles

Harnessing Gene Expression Profiles for the Identification of Drug Resistance Genes in Pediatric AML

Costa Bachas, MSc, Gerrit Jan Schuurhuis, PhD, C. Michel Zwaan, MD, PhD, Marry M. van den Heuvel-Eibrink, Monique L. Den Boer, PhD, Zinia J. Kwidama, BSc, Evelina S. De Bont, MD, PhD, Dirk Reinhardt, MD, Ursula Creutzig, MD, PhD, Valérie de Haas, MD, PhD, Yehuda Assaraf, PhD, Gertjan J.L. Kaspers, MD, PhD, Jacqueline Cloos, PhD

Blood (2012) 120 (21): 283.

https://doi.org/10.1182/blood.V120.21.283.283

Published: 2012

Journal Articles

Relapsed AML Patients with Mutational Shifts Harbor An Oligoclonal Primitive Cell Compartment at Presentation; Evidence for Clonal Selection towards Relapse

Costa Bachas, Gerrit Jan Schuurhuis, PhD, Zinia J. Kwidama, Angèle Kelder, Alexander N. Snel, Gertjan J. Kaspers, MD, PhD, Jacqueline Cloos, PhD

Blood (2010) 116 (21): 751.

https://doi.org/10.1182/blood.V116.21.751.751

Published: 2010

Journal Articles

High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine

Costa Bachas, Gerrit Jan Schuurhuis, Iris H. I. M. Hollink, Zinia J. Kwidama, Bianca F. Goemans, C. Michel Zwaan, Marry M. van den Heuvel-Eibrink, Eveline S. J. M. de Bont, Dirk Reinhardt, Ursula Creutzig, Valerie de Haas, Yehuda G. Assaraf, Gertjan J. L. Kaspers, Jacqueline Cloos

Blood (2010) 116 (15): 2752–2758.

https://doi.org/10.1182/blood-2010-03-276519

Published: 2010

Includes: Supplemental data

Journal Articles

Frequent Instability of Type I and II Aberrations Between Diagnosis and Relapse Observed in Pediatric Aml; Implications for Targeted Therapy and MRD Detection.

Costa Bachas, MSc, Gerrit-Jan Schuurhuis, Iris H.I.M. Hollink, MD, Bianca F. Goemans, MD, PhD, Dirk Reinhardt, MD, PhD, Christian M Zwaan, MD, PhD, Marry M. van den Heuvel, MD, PhD, Eveline S.J.M de Bont, Elisabeth R. Van Wering, Gertjan Kaspers, MD, PhD, Jacqueline Cloos, PhD

Blood (2009) 114 (22): 1624.

https://doi.org/10.1182/blood.V114.22.1624.1624

Published: 2009

Journal Articles

Changes in Type I Mutations Between Initial and Relapse Samples of Pediatric AML Patients Occur Frequently and Are Associated with Time to Relapse

Costa Bachas, MSc, Gerrit J. Schuurhuis, PhD, Lê D Huynh, BSc, Bianca F. Goemans, MD, PhD, D. Reinhardt, MD, PhD, Gertjan Kaspers, MD, PhD, Jacqueline Cloos, PhD

Blood (2008) 112 (11): 2540.

https://doi.org/10.1182/blood.V112.11.2540.2540

Published: 2008

NARROW

Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Impact of Hemodilution on Measurable Residual Disease Measured Via Flow-Cytometry in Acute Myeloid Leukemia Analyzed Using Subsequent Pulls

Prospective validation of the prognostic relevance of CD34 + CD38 – AML stem cell frequency in the HOVON-SAKK132 trial

Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Machine Learning-Based Flow Cytometry Diagnostics in Myelodysplastic Syndromes: Validation in the HOVON89 Clinical Trial (EudraCT 2008-002195-10)

Frequency and Prognostic Relevance of Gene Mutations in Pediatric AML Patients At First Relapse.

Harnessing Gene Expression Profiles for the Identification of Drug Resistance Genes in Pediatric AML

Relapsed AML Patients with Mutational Shifts Harbor An Oligoclonal Primitive Cell Compartment at Presentation; Evidence for Clonal Selection towards Relapse

High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine

Frequent Instability of Type I and II Aberrations Between Diagnosis and Relapse Observed in Pediatric Aml; Implications for Targeted Therapy and MRD Detection.

Changes in Type I Mutations Between Initial and Relapse Samples of Pediatric AML Patients Occur Frequently and Are Associated with Time to Relapse

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only